Another study with an enrolled population of HR+/HER2-/LN+ breast cancer patients is RxPONDER which failed to demonstrate an iDFS benefit with the application of chemotherapy in patients with a 70-gene test score of 0–25. This evidence concerns the gene ERBB2 and breast cancer.